U.S. Markets close in 2 hrs 8 mins

Edesa Biotech, Inc. (EDSA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.0350-0.0050 (-0.48%)
As of 01:28PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.0400
Bid1.0200 x 800
Ask1.0500 x 900
Day's Range1.0100 - 1.0800
52 Week Range0.7600 - 3.5300
Avg. Volume374,562
Market Cap20.031M
Beta (5Y Monthly)0.86
PE Ratio (TTM)N/A
EPS (TTM)-1.1050
Earnings DateMay 11, 2023 - May 15, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.00

    Edesa Biotech to Present Favorable Dermatitis Drug Results at American Academy of Dermatology Association Annual Meeting

    Edesa Biotech, Inc. announced today that the company has been selected to present clinical trial data from a Phase 2B multi-dose study of its EB01 drug candidate at a Late Breaking Abstract session of the American Academy of Dermatology Association (AAD) annual meeting being held March 17-21, 2023.


    Edesa Biotech and FDA Agree on Primary Endpoint for Phase 3 ARDS Drug Study

    Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported that the company and the U.S. Food and Drug Administration (FDA) have agreed on the primary endpoint and population for a pivotal Phase 3 study evaluating Edesa's monoclonal antibody candidate, EB05, as a therapy for hospitalized patients with a severe form of respiratory failure.

  • Zacks Small Cap Research

    EDSA: Positive News Flow to Start 2023…

    By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Edesa Biotech, Inc. (NASDAQ:EDSA) has started 2023 with multiple positive developments, including positive topline results for the Phase 2b clinical trial of EB01 as a treatment for chronic moderate-to-severe Allergic Contact Dermatitis (ACD), the FDA granting Fast Track designation to EB05, and Health Canada giving approval for a